NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA

Impact · against what's priced in

NTHI sees a modest positive catalyst from continued insider buying, though the primary clinical and financial milestones are already reflected in the stock. The open-market purchases by the CEO and CMO signal strong internal conviction heading into FDA filings, providing a psychological floor for the current valuation.

NTHI+0.30

No priced-in read yet